Back to resultsOpen Label Study in Adolescents and Children With Myotonic Disorders
Primary Purpose
Myotonic Dystrophy
Status
Recruiting
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
Mexiletine
Sponsored by
About this trial
This is an interventional treatment trial for Myotonic Dystrophy
Eligibility Criteria
Inclusion Criteria:
- Male or female patients aged ≥ 6 and < 18 years who are able to comply with the study requirements
- A genetically confirmed diagnosis of NDM or DM (DM1or DM2)
- Presence of clinical symptoms of myotonia (hand grip myotonia, myotonia in the leg muscles, any other myotonia symptoms)
- No significant cardiac abnormalities as determined by a cardiologist's assessment of the ECG and echocardiogram performed within 3 months prior to enrolment in the study. (If not done within 3 months before trial, electrocardiogram (ECG) and echocardiogram assessments will be performed at screening)
- No history of any significant liver disorder
- Patients receiving mexiletine treatment agree to stop treatment at least 7 days prior to initiation of treatment with Namuscla
- Patients receiving other antimyotonic treatment agree to stop treatment for at least 7 times the half-life of respective drug
- Laboratory investigations for haematology, biochemistry, and urinalysis at screening are within the normal range, or showing no clinically relevant abnormal values, as judged by the Investigator.
- Female patients of childbearing potential must be using an acceptable form of birth control as determined by the Investigator (e.g., oral contraception, implantable, injectable/transdermal hormonal contraception, intrauterine device (IUD), barrier methods), tubal ligation or are practicing abstinence.
- Patients able to provide assent to study participation and a parent or legal guardian to sign the written informed consent prior to study entry.
Exclusion Criteria:
Any contra-indication to mexiletine as listed in the Namuscla Summary of Product Characteristics (SmPC):
- Hypersensitivity to the active substance, or to any of the excipients
- Hypersensitivity to any local anaesthetic
- Ventricular tachyarrhythmia
- Complete heart block (i.e., third-degree atrioventricular block) or any heart block susceptible to evolve to complete heart block (first-degree atrioventricular block with markedly prolonged PR interval (≥ 200 ms) and/or wide QRS complex (≥ 120 ms), second-degree atrioventricular block, bundle branch block, bifascicular and trifascicular block),
- QT interval > 450ms
- Myocardial infarction (acute or past), or abnormal Q-waves
- Symptomatic coronary artery disease
- Heart failure with ejection fraction <50%
- Atrial tachyarrhythmia, fibrillation or flutter
Sinus node dysfunction (including sinus rate < 50 bpm)
• Co-administration with medicinal products inducing torsades de pointes (class Ia, Ic, III antiarrhythmics): Co-administration of mexiletine and antiarrhythmics inducing torsades de pointesclass Ia: quinidine, procainamide, disopyramide, ajmaline; class Ic: encainide, flecainide, propafenone, moricizine; class III: amiodarone, sotalol, ibutilide, dofetilide, dronedarone, vernakalant) increases the risk of potentially lethal torsades de pointes.
- Co-administration with medicinal products with narrow therapeutic index
- Any other neurological or psychiatric condition that might affect the study assessments
- Any clinically significant illness, laboratory findings, ECG, or other clinical symptoms, which in the opinion of the Investigator could affect the patient's optimal participation in the study
- Strong inducer or inhibitor of CYP2D6 or CYP1A2 within 7 days prior to study drug administration
- Any concurrent illness, or medications which could affect the muscle function
- Seizure disorder, diabetes mellitus requiring treatment by insulin
- Pregnant or breastfeeding
- Concurrent participation in any other clinical trial.
Sites / Locations
- Hôpital Necker-Enfants-MaladesRecruiting
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Cohort 1 and 2
Arm Description
7 patients aged 12 to < 18 years , inclusive in cohort-1 7 patients aged 6 to < 12 years, inclusive in cohort-2
Outcomes
Primary Outcome Measures
Number and frequency of adverse events (AEs)/serious adverse events (SAEs)
Number and frequency of adverse events (AEs)/serious adverse events (SAEs), throughout the study while on treatment with Namuscla
Incidence of adverse events of special interest (AESI)
Incidence of adverse events of special interest (AESI)
Changes in ECG assessments from baseline
On resting ECG any alteration will be noted:
Mild ECG abnormalities: PR interval ≥200 ms and QRS duration ≥100 ms
Severe ECG abnormalities: PR interval ≥240 ms, QRS duration ≥120 ms, second or third degree AV block and a rhythm other than sinus
Efficacy of Namuscla treatment on the clinical outcomes based on the following functional evaluation mean change in Visual Analogue Scale (VAS) for muscle stiffness.
Mean change in Visual Analogue Scale (VAS) for muscle stiffness. The VAS is constructed as an absolute measure, with a 10 cm straight horizontal line having the endpoints "no stiffness at all" and "stiffness as worst possible". The patient's responses will be scored on the line to the nearest millimetre (a 100-point scale). (myotonia severity).
Efficacy of Namuscla treatment on the clinical outcomes(change from baseline to Days 14, 28, 42 and 56, respectively) based on the following functional evaluation
The score of handgrip myotonia as quantitatively measured using a commercially available grip dynamometer and computerised capture system. In standardised conditions (i.e. in a room at controlled temperature, after a definite period of rest), maximum voluntary contractions following forced right hand grip will be recorded and the time to relax from 90% to 5% of maximal force will be determined using automated analysis software
Secondary Outcome Measures
Mean change in VAS score for muscle pain, weakness and fatigue
The VAS is constructed as an absolute measure, with a 10 cm straight horizontal line having the endpoints "no stiffness at all" and "stiffness as worst possible". The patient's responses will be scored on the line to the nearest millimetre (a 100-point scale). The score of stiffness severity as self-reported by the patient on a 10-point VAS will be used for adolescents and children older than 8 years and will be summarised descriptively by visit
Clinical myotonia assessment for mean change in time to open the eyes
Mean change in time to open the eyes after forced eye closure as measured on a stopwatch (when eyelid myotonia present). Subjects will be asked to squeeze their eyes closed for 5 seconds then rapidly open them for 5 seconds then rapidly open. Five trials of each manoeuvre will be performed in sequence at each visit and the time measured on a stopwatch
Clinical myotonia assessment of clinical change in flexor myotonia
Clinical change in flexor myotonia (right hand flexor muscles). Subjects will be asked to make a tight fist for 5 seconds then rapidly open. Five trials of each manoeuvre will be performed in sequence at each visit and the time measured on a stopwatch
Clinical myotonia assessment of mean change in time to perform Timed-up and go (TUG) test
Mean change in time to perform Timed-up and go (TUG) test. Measures, in seconds, the time taken by an individual to stand up from a standard arm chair (approximate seat height of 46 cm, arm height 65 cm), walk a distance of 3 meters (approximately 10 feet), turn, walk back to the chair, and sit down.
Mean change in health-related quality-of-life as measured by the Paediatric Quality of Life (PedsQL) score
Mean change from baseline to Day 56, respectively in health-related quality-of-life as measured by the Paediatric Quality of Life (PedsQL) score. These multidimensional scales assess the frequency of health problems using generic and disease-specific approaches, respectively. Subjects and/or parent or proxies report a score of 0 to 4 (never to almost always) and questionnaires are tailored to age groups.
Clinical Global Impression (CGI) scores (efficacy and tolerability) evaluated by the patient
Clinical Global Impression (CGI) scores (efficacy and tolerability) evaluated by the patient, a parent or proxy and by the investigator at baseline and Day 56. Evaluated on a 4-point scale as very efficient, good, fair or poor.
Mean change in Myotonia Behaviour Scale (MBS) scores
Mean change from baseline to Day 56 in Myotonia Behaviour Scale (MBS) scores The Myotonia Behaviour Scale (MBS) (Hammaren et al., 2005) 0 No stiffness
Some stiffness exists, which can be ignored
Some stiffness exists, which can be ignored at times, but doesn't impair daily activities
Stiffness exists, which demands a higher level of mental awareness when performing some duties and activities
Severe stiffness exists, which impairs every duty and activity
Incapacitating stiffness exists, which demands constant moving not to be totally locked up, with regard to movement
Changes in clinical laboratory values for laboratory safety assessments - Potassium
Changes in Potassium values from baseline to Day 56.
Acceptability of the capsule formulation with respect to the swallowability.
Acceptability of the capsule formulation with respect to the swallowability. It will be assessed by interviewing patients and their caregivers at Day 56.
Palatability of alternative administration
Palatability of alternative administration (capsule content with milk/juice or sprinkled on food) by 5-point facial hedonic scale correlated with 100-point Visual Analogue Scale (VAS) at each clinic visit
Changes in clinical laboratory values from baseline to Day 56 for laboratory safety assessments - Changes in Magnesium values
Changes in Magnesium values from baseline to Day 56.
Changes in clinical laboratory values from baseline to Day 56 for laboratory safety assessments - Changes in Sodium values
Changes in Sodium values from baseline to Day 56.
Changes in clinical laboratory values from baseline to Day 56 for laboratory safety assessments - Changes in Calcium values
Changes in Calcium values from baseline to Day 56.
Changes in clinical laboratory values from baseline to Day 56 for laboratory safety assessments - Changes in Chloride values
Changes in Chloride values from baseline to Day 56.
Mean change in Faces scale for muscle pain, weakness and fatigue
A Faces (or other symbol) scale for children aged 6 to 8 years will be used to measure the score of muscle stiffness (myotonia severity). Faces scale will be used to assess pain, weakness and tiredness in study participants with a 10 cm straight horizontal line having the endpoints "no [symptom] at all" and "[symptom] as worst possible"
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04624750
Brief Title
Open Label Study in Adolescents and Children With Myotonic Disorders
Official Title
An Open-label, Non-Comparative Study to Evaluate the Steady-State Pharmacokinetics, Safety, and Efficacy of Mexiletine in Adolescents and Children With Myotonic Disorders
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 3, 2021 (Actual)
Primary Completion Date
March 12, 2024 (Anticipated)
Study Completion Date
March 12, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lupin Ltd.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is an open-label, multi-centre, single arm, interventional study to describe the steady-state PK, safety, and efficacy of mexiletine in paediatric patients (6 to <18 years of age) with myotonic disorders.
Detailed Description
This is an open-label, multi-centre, single arm, interventional study to describe the steady-state PK, safety, and efficacy of mexiletine in paediatric patients (6 to <18 years of age) with myotonic disorders.
Patients who meet the eligibility criteria will be enrolled stepwise, sequentially in 2 cohorts by age groups.
Cohort 1 - Adolescents aged 12 to <18 years, will be enrolled first. If no safety concerns are observed (based on data evaluation by the Data Safety Monitoring Board [DSMB]), and the dose for the age group 6 to <12 years is confirmed by PK model, enrolment for Cohort 2 will begin.
Cohort 2 - Children aged 6 to <12 years, will be enrolled. The overall treatment duration for each cohort will be approximately 56 days (8 weeks): a dose titration phase of 4 weeks and the maintenance phase of 4 weeks. The overall study duration would be approximately 22 months.
Dose titration phase: In this phase, patients will receive mexiletine starting at an age appropriate dose (as evaluated by the investigator and based on body weight) at a frequency of once a day. Dose will be up-titrated every 14 days based on tolerability of mexiletine up to a maximum of three-times a day as assessed by investigator.
Maintenance phase: During the maintenance phase, patients will continue to receive mexiletine at the best-tolerated dose from the titration phase for further 4 weeks. Following completion, all participants will be offered follow-up in PIP Study 7 (MEX-NM-303) (EudraCT: 2019-003758-97).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myotonic Dystrophy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Model Description
This is an open-label, multi-centre, single arm, interventional, study to evaluate the safety, steady-state PK, and efficacy of mexiletine for the treatment of myotonia in paediatric population aged 6 to < 18 years.
The study comprises a screening period of 30 days, a dose-titration period of 4 weeks, and a maintenance period of 4 weeks. After last visit, all patients will be offered follow-up in clinical study MEX-NM-303 (PIP Study 7).
Masking
None (Open Label)
Allocation
N/A
Enrollment
14 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Cohort 1 and 2
Arm Type
Other
Arm Description
7 patients aged 12 to < 18 years , inclusive in cohort-1 7 patients aged 6 to < 12 years, inclusive in cohort-2
Intervention Type
Drug
Intervention Name(s)
Mexiletine
Other Intervention Name(s)
Namuscla ™
Intervention Description
Patients will be enrolled sequentially into 2 cohorts. Cohort 1 - (patients aged 12 to < 18 years): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.
Cohort 2 - (patients aged 6 to < 12 years,): approximately 8 weeks - 4 weeks of dose titration period + 4 weeks of maintenance period.
Enrolment for Cohort 2 will begin after initial safety assessment of patients in Cohort 1 by the DSMB and no safety concerns are observed. The dose level for cohort 2 will be confirmed by PK modelling study.
Primary Outcome Measure Information:
Title
Number and frequency of adverse events (AEs)/serious adverse events (SAEs)
Description
Number and frequency of adverse events (AEs)/serious adverse events (SAEs), throughout the study while on treatment with Namuscla
Time Frame
Baseline to Day 56
Title
Incidence of adverse events of special interest (AESI)
Description
Incidence of adverse events of special interest (AESI)
Time Frame
Baseline to Day 56
Title
Changes in ECG assessments from baseline
Description
On resting ECG any alteration will be noted:
Mild ECG abnormalities: PR interval ≥200 ms and QRS duration ≥100 ms
Severe ECG abnormalities: PR interval ≥240 ms, QRS duration ≥120 ms, second or third degree AV block and a rhythm other than sinus
Time Frame
Baseline to Day 56
Title
Efficacy of Namuscla treatment on the clinical outcomes based on the following functional evaluation mean change in Visual Analogue Scale (VAS) for muscle stiffness.
Description
Mean change in Visual Analogue Scale (VAS) for muscle stiffness. The VAS is constructed as an absolute measure, with a 10 cm straight horizontal line having the endpoints "no stiffness at all" and "stiffness as worst possible". The patient's responses will be scored on the line to the nearest millimetre (a 100-point scale). (myotonia severity).
Time Frame
Baseline to Day 56
Title
Efficacy of Namuscla treatment on the clinical outcomes(change from baseline to Days 14, 28, 42 and 56, respectively) based on the following functional evaluation
Description
The score of handgrip myotonia as quantitatively measured using a commercially available grip dynamometer and computerised capture system. In standardised conditions (i.e. in a room at controlled temperature, after a definite period of rest), maximum voluntary contractions following forced right hand grip will be recorded and the time to relax from 90% to 5% of maximal force will be determined using automated analysis software
Time Frame
Baseline to Day 56
Secondary Outcome Measure Information:
Title
Mean change in VAS score for muscle pain, weakness and fatigue
Description
The VAS is constructed as an absolute measure, with a 10 cm straight horizontal line having the endpoints "no stiffness at all" and "stiffness as worst possible". The patient's responses will be scored on the line to the nearest millimetre (a 100-point scale). The score of stiffness severity as self-reported by the patient on a 10-point VAS will be used for adolescents and children older than 8 years and will be summarised descriptively by visit
Time Frame
Baseline - Day 56
Title
Clinical myotonia assessment for mean change in time to open the eyes
Description
Mean change in time to open the eyes after forced eye closure as measured on a stopwatch (when eyelid myotonia present). Subjects will be asked to squeeze their eyes closed for 5 seconds then rapidly open them for 5 seconds then rapidly open. Five trials of each manoeuvre will be performed in sequence at each visit and the time measured on a stopwatch
Time Frame
Baseline - Day 56
Title
Clinical myotonia assessment of clinical change in flexor myotonia
Description
Clinical change in flexor myotonia (right hand flexor muscles). Subjects will be asked to make a tight fist for 5 seconds then rapidly open. Five trials of each manoeuvre will be performed in sequence at each visit and the time measured on a stopwatch
Time Frame
Baseline - Day 56
Title
Clinical myotonia assessment of mean change in time to perform Timed-up and go (TUG) test
Description
Mean change in time to perform Timed-up and go (TUG) test. Measures, in seconds, the time taken by an individual to stand up from a standard arm chair (approximate seat height of 46 cm, arm height 65 cm), walk a distance of 3 meters (approximately 10 feet), turn, walk back to the chair, and sit down.
Time Frame
Baseline - Day 56
Title
Mean change in health-related quality-of-life as measured by the Paediatric Quality of Life (PedsQL) score
Description
Mean change from baseline to Day 56, respectively in health-related quality-of-life as measured by the Paediatric Quality of Life (PedsQL) score. These multidimensional scales assess the frequency of health problems using generic and disease-specific approaches, respectively. Subjects and/or parent or proxies report a score of 0 to 4 (never to almost always) and questionnaires are tailored to age groups.
Time Frame
Baseline - Day 56
Title
Clinical Global Impression (CGI) scores (efficacy and tolerability) evaluated by the patient
Description
Clinical Global Impression (CGI) scores (efficacy and tolerability) evaluated by the patient, a parent or proxy and by the investigator at baseline and Day 56. Evaluated on a 4-point scale as very efficient, good, fair or poor.
Time Frame
Baseline - Day 56
Title
Mean change in Myotonia Behaviour Scale (MBS) scores
Description
Mean change from baseline to Day 56 in Myotonia Behaviour Scale (MBS) scores The Myotonia Behaviour Scale (MBS) (Hammaren et al., 2005) 0 No stiffness
Some stiffness exists, which can be ignored
Some stiffness exists, which can be ignored at times, but doesn't impair daily activities
Stiffness exists, which demands a higher level of mental awareness when performing some duties and activities
Severe stiffness exists, which impairs every duty and activity
Incapacitating stiffness exists, which demands constant moving not to be totally locked up, with regard to movement
Time Frame
Baseline - Day 56
Title
Changes in clinical laboratory values for laboratory safety assessments - Potassium
Description
Changes in Potassium values from baseline to Day 56.
Time Frame
Baseline - Day 56
Title
Acceptability of the capsule formulation with respect to the swallowability.
Description
Acceptability of the capsule formulation with respect to the swallowability. It will be assessed by interviewing patients and their caregivers at Day 56.
Time Frame
Baseline - Day 56
Title
Palatability of alternative administration
Description
Palatability of alternative administration (capsule content with milk/juice or sprinkled on food) by 5-point facial hedonic scale correlated with 100-point Visual Analogue Scale (VAS) at each clinic visit
Time Frame
Baseline - Day 56
Title
Changes in clinical laboratory values from baseline to Day 56 for laboratory safety assessments - Changes in Magnesium values
Description
Changes in Magnesium values from baseline to Day 56.
Time Frame
Baseline - Day 56
Title
Changes in clinical laboratory values from baseline to Day 56 for laboratory safety assessments - Changes in Sodium values
Description
Changes in Sodium values from baseline to Day 56.
Time Frame
Baseline - Day 56
Title
Changes in clinical laboratory values from baseline to Day 56 for laboratory safety assessments - Changes in Calcium values
Description
Changes in Calcium values from baseline to Day 56.
Time Frame
Baseline - Day 56
Title
Changes in clinical laboratory values from baseline to Day 56 for laboratory safety assessments - Changes in Chloride values
Description
Changes in Chloride values from baseline to Day 56.
Time Frame
Baseline - Day 56
Title
Mean change in Faces scale for muscle pain, weakness and fatigue
Description
A Faces (or other symbol) scale for children aged 6 to 8 years will be used to measure the score of muscle stiffness (myotonia severity). Faces scale will be used to assess pain, weakness and tiredness in study participants with a 10 cm straight horizontal line having the endpoints "no [symptom] at all" and "[symptom] as worst possible"
Time Frame
Baseline - Day 56
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female patients aged ≥ 6 and < 18 years who are able to comply with the study requirements
A genetically confirmed diagnosis of NDM or DM (DM1or DM2)
Presence of clinical symptoms of myotonia (hand grip myotonia, myotonia in the leg muscles, any other myotonia symptoms)
No significant cardiac abnormalities as determined by a cardiologist's assessment of the ECG and echocardiogram performed within 3 months prior to enrolment in the study. (If not done within 3 months before trial, electrocardiogram (ECG) and echocardiogram assessments will be performed at screening)
No history of any significant liver disorder
Patients receiving mexiletine treatment agree to stop treatment at least 7 days prior to initiation of treatment with Namuscla
Patients receiving other antimyotonic treatment agree to stop treatment for at least 7 times the half-life of respective drug
Laboratory investigations for haematology, biochemistry, and urinalysis at screening are within the normal range, or showing no clinically relevant abnormal values, as judged by the Investigator.
Female patients of childbearing potential must be using an acceptable form of birth control as determined by the Investigator (e.g., oral contraception, implantable, injectable/transdermal hormonal contraception, intrauterine device (IUD), barrier methods), tubal ligation or are practicing abstinence.
Patients able to provide assent to study participation and a parent or legal guardian to sign the written informed consent prior to study entry.
Exclusion Criteria:
Any contra-indication to mexiletine as listed in the Namuscla Summary of Product Characteristics (SmPC):
Hypersensitivity to the active substance, or to any of the excipients
Hypersensitivity to any local anaesthetic
Ventricular tachyarrhythmia
Complete heart block (i.e., third-degree atrioventricular block) or any heart block susceptible to evolve to complete heart block (first-degree atrioventricular block with markedly prolonged PR interval (≥ 200 ms) and/or wide QRS complex (≥ 120 ms), second-degree atrioventricular block, bundle branch block, bifascicular and trifascicular block),
QT interval > 450ms
Myocardial infarction (acute or past), or abnormal Q-waves
Symptomatic coronary artery disease
Heart failure with ejection fraction <50%
Atrial tachyarrhythmia, fibrillation or flutter
Sinus node dysfunction (including sinus rate < 50 bpm)
• Co-administration with medicinal products inducing torsades de pointes (class Ia, Ic, III antiarrhythmics): Co-administration of mexiletine and antiarrhythmics inducing torsades de pointesclass Ia: quinidine, procainamide, disopyramide, ajmaline; class Ic: encainide, flecainide, propafenone, moricizine; class III: amiodarone, sotalol, ibutilide, dofetilide, dronedarone, vernakalant) increases the risk of potentially lethal torsades de pointes.
Co-administration with medicinal products with narrow therapeutic index
Any other neurological or psychiatric condition that might affect the study assessments
Any clinically significant illness, laboratory findings, ECG, or other clinical symptoms, which in the opinion of the Investigator could affect the patient's optimal participation in the study
Strong inducer or inhibitor of CYP2D6 or CYP1A2 within 7 days prior to study drug administration
Any concurrent illness, or medications which could affect the muscle function
Seizure disorder, diabetes mellitus requiring treatment by insulin
Pregnant or breastfeeding
Concurrent participation in any other clinical trial.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nikki Adetoro
Phone
443-447-4534
Email
NikkiAdetoro@lupin.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christine Barnérias, MD
Organizational Affiliation
Hopital universitaire Necker-Enfants Malades
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpital Necker-Enfants-Malades
City
Paris
Country
France
Individual Site Status
Recruiting
12. IPD Sharing Statement
Learn more about this trial
Open Label Study in Adolescents and Children With Myotonic Disorders
We'll reach out to this number within 24 hrs